Federal Register / Vol. 85, No. 232 / Wednesday, December 2, 2020 / Notices 77467 

PICOTS (POPULATIONS, INTERVENTIONS, COMPARATORS, OUTCOMES, TIMING, SETTINGS)—Continued 

PICOTS element Inclusion criteria Exclusion criteria 

Outcomes ................ All KQs: Primary efficacy outcomes (i.e., pain, function, disability, pain interference); harms and adverse effects 

(e.g., dizziness, nausea, sedation, development of cannabis use disorder); secondary outcomes (i.e., psychological distress including depression and anxiety, quality 

of life, opioid use, sleep quality, sleep disturbance, health 

care utilization).

All KQs: Other outcomes. 

Time of follow-up ..... All KQs: short term (1 to <6 months), intermediate term (6 

to <12 months), long term (≥1 year).

All KQs: studies with <1-month of treatment or followup 

after treatment. 

Setting ..................... All KQs: Any nonhospital setting or setting of self-directed 

care.

All KQs: Hospital care, hospice care, emergency department care. 

Study design ............ All KQs: RCTs; observational studies with a concurrent 

control group for harms, and to fill gaps in the evidence 

for benefits.

All KQs: Other study designs. 

Abbreviations: RCT = randomized controlled trial. 

Dated: November 27, 2020. 

Marquita Cullom, 

Associate Director. 

[FR Doc. 2020–26570 Filed 12–1–20; 8:45 am] 

BILLING CODE 4160–90–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, CDC, pursuant to 

Public Law 92–463. The grant 

applications and the discussions could 

disclose confidential trade secrets or 

commercial property such as patentable 

material, and personal information 

concerning individuals associated with 

the grant applications, the disclosure of 

which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel (SEP)- 

RFA–PS–21–003, PrEP Choice: 

Increasing the Use of HIV Pre-exposure 

Prophylaxis in an Era of Choices; and 

RFA–PS–21–004, Implementing and 

Evaluating a Data-to-Care Rx Strategy. 

Date: February 23–24, 2021. 

Time: 10:00 a.m.–5:00 p.m., EST. 

Place: Teleconference, Centers for 

Disease Control and Prevention, Room 

1080, 8 Corporate Square Boulevard, 

Atlanta, Georgia 30329–4027. 

Agenda: To review and evaluate grant 

applications. 

FOR FURTHER INFORMATION CONTACT: 

Gregory Anderson, M.S., M.P.H., 

Scientific Review Officer, CDC, 1600 

Clifton Road NE, Mailstop US8–1, 

Atlanta, Georgia 30329–4027, (404) 718– 

8833, GAnderson@cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2020–26558 Filed 12–1–20; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2020–0121] 

Advisory Committee on Immunization 

Practices (ACIP) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting and request 

for comment. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC), announces the 

following meeting of the Advisory 

Committee on Immunization Practices 

(ACIP). This meeting is open to the 

public. The meeting will be webcast live 

via the World Wide Web. 

DATES: The meeting will be held on 

December 1, 2020 from 2:00 p.m. to 5:00 

p.m., EST (times subject to change). 

Written comments must be received 

on or before December 3, 2020. 

ADDRESSES: For more information on 

ACIP please visit the ACIP website: 

http://www.cdc.gov/vaccines/acip/ 

index.html. 

You may submit comments, identified 

by Docket No. CDC–2020–0121 by any 

of the following methods: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Docket No. CDC–2020–0121, 

c/o Attn: November 23, 2020 ACIP 

Meeting, Centers for Disease Control 

and Prevention, 1600 Clifton Road NE, 

MS H24–8, Atlanta, GA 30329–4027. 

Instructions: All submissions received 

must include the Agency name and 

Docket Number. All relevant comments 

received in conformance with the 

https://www.regulations.gov suitability 

policy will be posted without change to 

https://www.regulations.gov, including 

any personal information provided. For 

access to the docket to read background 

documents or comments received, go to 

https://www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: 

Stephanie Thomas, ACIP Committee 

Management Specialist, Centers for 

Disease Control and Prevention, 

National Center for Immunization and 

Respiratory Diseases, 1600 Clifton Road 

NE, MS–H24–8, Atlanta, GA 30329– 

4027; Telephone: 404–639–8367; Email: 

ACIP@cdc.gov. 

SUPPLEMENTARY INFORMATION: In 

accordance with 41 CFR 102–3.150(b), 

less than 15 calendar days’ notice is